FDA Drug Recalls
17,898 recalls, newest first
Class II · Moderate risk Ongoing Jan 21, 2025
Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for…
Class II · Moderate risk Ongoing Jan 21, 2025
Reason Out of Specification for Dissolution
Class II · Moderate risk Ongoing Jan 17, 2025
Reason cGMP Deviations: Product intended for quarantine was inadvertently distributed.
Class III · Low risk Terminated Jan 17, 2025
Reason Labeling: Missing Label: The finished product potentially missing the labeling with the drug facts panel, bar code and directions for use.
Class III · Low risk Completed Jan 16, 2025
Reason Failed Tablet/Capsule Specifications: Missing tab ID on either side of the tablet
Class II · Moderate risk Terminated Jan 13, 2025
Reason CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake…
Class II · Moderate risk Ongoing Jan 10, 2025
Reason Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
Class II · Moderate risk Ongoing Jan 8, 2025
Reason Failed stability specifications: during routine stability monitoring quality concerns were identified. Physical separation for ingredients was…
Class III · Low risk Terminated Jan 7, 2025
Reason Superpotent; sodium benzoate preservative
Class II · Moderate risk Ongoing Jan 7, 2025
Reason Presence of Foreign Tablets/Capsules
Class II · Moderate risk Terminated Dec 30, 2024
Reason Presence of Foreign Tablets/Capsules: A Paracetamol 500 mg tablet was found in a 1000-count bottle of Metformin HCL ER Tablets USP, 500 mg.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 27, 2024
Reason Presence of Particulate Matter: A market complaint was received of a glass piece in the vial.
Class I · High risk Ongoing Dec 23, 2024
Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules
Class I · High risk Ongoing Dec 23, 2024
Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules
Class II · Moderate risk Ongoing Dec 23, 2024
Reason CGMP Deviations; product intended for quarantine was inadvertently distributed
Class II · Moderate risk Terminated Dec 23, 2024
Reason Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Class II · Moderate risk Terminated Dec 23, 2024
Reason Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Class I · High risk Ongoing Dec 20, 2024
Reason Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP)
Class II · Moderate risk Terminated Dec 20, 2024
Reason Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term…
Class III · Low risk Ongoing Dec 19, 2024
Reason Failed Tablet/Capsule Specifications: Illegible product identification for the unit dose configuration only.
Class II · Moderate risk Terminated Dec 19, 2024
Reason Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.
Class II · Moderate risk Terminated Dec 19, 2024
Reason Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.